Vascor Side Effects
Generic Name: bepridil
Note: This document contains side effect information about bepridil. Some of the dosage forms listed on this page may not apply to the brand name Vascor.
Applies to bepridil: oral tablet
Bepridil (the active ingredient contained in Vascor) has generally been well-tolerated. Although adverse side effects have been reported in up to 87% of patients, most were mild to moderate in severity.[Ref]
Cardiovascular side effects have been uncommon, but potentially serious. The use of bepridil (the active ingredient contained in Vascor) has been associated with dose-related QT segment prolongation in up to 80% of patients, which may be associated with torsades de pointes in up to 1% of patients and ventricular tachycardia or fibrillation in up to 3% of patients. The manufacturer has recommended that the dose be reduced if the QT interval exceeds 0.52 seconds during treatment.
Serious arrhythmias associated with the use of bepridil have been more prevalent among patients with increased QT segment lengthening (on ECG), hypokalemia, advanced age, and among female patients.[Ref]
Hepatic side effects including elevated serum hepatic enzyme concentrations have been observed in 1% of patients.[Ref]
Two patients who developed leukopenia were elderly and diabetic. One surviving patient recovered after bepridil was discontinued.
In another case, a 72-year-old man with severe angina pectoris developed a fever and chills associated with an absolute neutrophil count of 35 per mm3 six weeks after switching from diltiazem and nitrates to bepridil and nitrates. A bone marrow biopsy revealed profound myeloid hypoplasia. The patient recovered after discontinuation of bepridil, institution of granulocyte colony-stimulating factor, and broad-spectrum antibiotics.[Ref]
A 72-year-old man with coronary artery disease, status post myocardial infarction, and congestive heart failure developed a dry cough and dyspnea 1 week after beginning bepridil (the active ingredient contained in Vascor) Associated findings included hypoxemia, chest X-ray evidence of a left perihilar infiltrate, and interstitial pulmonary fibrosis per a transbronchial biopsy. The patient's signs and symptoms resolved after substitution of bepridil with diltiazem and institution of oxygen and prednisone therapy. The recent history of congestive heart failure may have predisposed this patient to the adverse effects of bepridil.
The authors of this case report found no other well-described cases of interstitial pulmonary disease associated with bepridil, but noted approximately four incidentally-described cases of inflammatory pulmonary infiltrates associated with bepridil either from the manufacturer or from large studies.[Ref]
Respiratory side effects including at least one case of pulmonary fibrosis associated with bepridil has been reported.[Ref]
1. Singh BN "Comparative efficacy and safety of bepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem. The Bepridil Collaborative Study Group." Am J Cardiol 68 (1991): 306-12
2. Narahara KA, Singh BN, Karliner JS, Corday SR, Hossack KF "Bepridil hydrochloride compared with placebo in patients with stable angina pectoris." Am J Cardiol 69 (1992): d37-42
3. Hollingshead LM, Faulds D, Fitton A "Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris." Drugs 44 (1992): 835-57
4. Shapiro W "Comparative efficacy of bepridil versus placebo in angina pectoris: treatment and withdrawal studies." Am J Cardiol 69 (1992): d43-9
5. Singh BN "Bepridil therapy: guidelines for patient selection and monitoring of therapy." Am J Cardiol 69 (1992): d79-85
6. Singh BN "Safety profile of bepridil determined from clinical trials in chronic stable angina in the United States." Am J Cardiol 69 (1992): d68-74
7. Coumel P "Safety of bepridil: from review of the European data." Am J Cardiol 69 (1992): d75-8
8. Alpert JS, Coumel P, Greeff K, Krikler DM, Remme WJ, Schonbaum E, Verduyn CW "Bepridil: a review of its pharmacology and clinical efficacy as an anti-anginal agent with anti-arrhythmic properties." Pharmatherapeutica 4 (1985): 195-222
9. "Product Information. Vascor (bepridil)." McNeil Pharmaceutical, Raritan, NJ.
10. Weiss RJ "Bepridil and agranulocytosis." Am Heart J 125 (1993): 1819-20
11. Vasilomanolakis EC, Goldberg NM "Bepridil-induced pulmonary fibrosis." Am Heart J 126 (1993): 1016-7
Some side effects may not be reported. You may report them to the FDA.